GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (STU:1KA) » Definitions » EV-to-FCF

GH Research (STU:1KA) EV-to-FCF : -11.74 (As of Apr. 04, 2025)


View and export this data going back to 2024. Start your Free Trial

What is GH Research EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, GH Research's Enterprise Value is €459.85 Mil. GH Research's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-39.17 Mil. Therefore, GH Research's EV-to-FCF for today is -11.74.

The historical rank and industry rank for GH Research's EV-to-FCF or its related term are showing as below:

STU:1KA' s EV-to-FCF Range Over the Past 10 Years
Min: -11.73   Med: 0   Max: 0
Current: -11.73

STU:1KA's EV-to-FCF is ranked worse than
100% of 447 companies
in the Biotechnology industry
Industry Median: 2.69 vs STU:1KA: -11.73

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-04), GH Research's stock price is €8.45. GH Research's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.693. Therefore, GH Research's PE Ratio (TTM) for today is At Loss.


GH Research EV-to-FCF Historical Data

The historical data trend for GH Research's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GH Research EV-to-FCF Chart

GH Research Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial - -60.89 -12.93 -4.22 -5.09

GH Research Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.22 -11.00 -12.00 -4.97 -5.09

Competitive Comparison of GH Research's EV-to-FCF

For the Biotechnology subindustry, GH Research's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GH Research's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GH Research's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where GH Research's EV-to-FCF falls into.


;
;

GH Research EV-to-FCF Calculation

GH Research's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=459.849/-39.17
=-11.74

GH Research's current Enterprise Value is €459.85 Mil.
GH Research's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-39.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GH Research  (STU:1KA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

GH Research's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8.45/-0.693
=At Loss

GH Research's share price for today is €8.45.
GH Research's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.693.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


GH Research EV-to-FCF Related Terms

Thank you for viewing the detailed overview of GH Research's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GH Research Business Description

Traded in Other Exchanges
Address
Dawson Street, Joshua Dawson House, Dublin 2, IRL, D02 RY95
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

GH Research Headlines

No Headlines